A 52-year-old woman with HBsAg-positive cirrhosis and a 2.8 cm nodule in segment 7 (confirmed HCC by imaging) is deemed unfit for surgery due to poor hepatic reserve (Child-Pugh C). She has ECOG performance status 2 and mild ascites. Which is the most appropriate drug of choice for her management?

Explanation

## Systemic Therapy Selection in Advanced HCC with Poor Hepatic Reserve **Key Point:** Sorafenib remains the preferred choice in patients with advanced HCC and significant hepatic decompensation (Child-Pugh C) or poor performance status (ECOG ≥2), as it has the most robust safety data in this population and does not require intact immune function [cite:Harrison 21e Ch 297]. ### Clinical Context: Why Not Atezolizumab + Bevacizumab? **High-Yield:** Atezolizumab + bevacizumab is contraindicated or requires extreme caution in: - **Child-Pugh C cirrhosis:** Risk of hepatic decompensation and treatment-related hepatotoxicity is prohibitive. - **ECOG ≥2 performance status:** Patient is largely bedridden; immunotherapy-related toxicity may be fatal. - **Ascites with poor reserve:** Combination therapy may precipitate variceal bleeding or hepatic encephalopathy. ### Comparative Safety Profile in Decompensated Cirrhosis | Drug | Hepatotoxicity Risk | ECOG Tolerance | Child-Pugh C Use | Immune Activation | |------|-------------------|-----------------|------------------|-------------------| | **Sorafenib** | Low–moderate | ECOG 0–2 | Acceptable | No | | Atezolizumab + bevacizumab | Moderate–high | ECOG 0–1 only | Contraindicated | Yes (risk of flare) | | Lenvatinib | Moderate | ECOG 0–1 | Caution | No | | Regorafenib | Moderate–high | ECOG 0–1 | Caution | No | **Clinical Pearl:** Sorafenib was the only agent with proven survival benefit in the SHARP trial (2008) specifically in patients with advanced HCC and preserved to moderately impaired liver function. Its long track record in decompensated cirrhosis makes it the safest choice when immunotherapy is not feasible. **Warning:** Do not use atezolizumab + bevacizumab in Child-Pugh C patients—risk of immune-mediated hepatic flare and fatal decompensation is unacceptable. Lenvatinib and regorafenib also require careful patient selection in this setting.